Paricalcitol

Paricalcitol, a vitamin D analogue, is a vitamin D receptor agonist, used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.

Product Specifications

CAS Number

[131918-61-1]

UNSPSC

12352211

Hazard Statement

H225, H319

Target

VD/VDR

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Paricalcitol.html

Purity

99.96

Solubility

DMSO : 100 mg/mL (ultrasonic) |Ethanol : 12.5 mg/mL (ultrasonic)

Smiles

C[C@]([C@]([C@H](C)/C=C/[C@H](C)C(C)(C)O)([H])CC1)(CCC/2)[C@]1([H])C2=C\C=C3C[C@@H](O)C[C@H](O)C/3

Molecular Formula

C27H44O3

Molecular Weight

416.64

Precautions

H225, H319

References & Citations

[1]Martinez-Moreno JM, et al. In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/beta-catenin activation. Am J Physiol Renal Physiol. 2012 Aug 8.|[2]Meems LM, et al. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol. 2012 Jul 16;132 (3-5) :282-289.